Inhibitors of tumor necrosis factor-α: Promising agents for the treatment of multiple sclerosis?

Multiple Sclerosis

Volumn 1, Issue 6, 1996, Pages 376-378

  Hohlfeld, Reinhard ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

Author keywords

Immunotherapy; Multiple sclerosis; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL; DRUG ANTAGONISM; HUMAN; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030178426     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600100619     Document Type: Article

References (28)

1. Hohlfeld R, Lucas K, eds. (1995) Cytokine networks in multiple sclerosis. Neurology 45 (Suppl. 6): 1-55.
2. Beutler B, Cerami A. (1987) Cachectin: More than a tumor necrosis factor. N Engl J Med 316: 379-385.
3. Beutler B, Cerami A. (1989) The biology of cachectin/TNF - A primary mediator of the host response. Annu Rev Immunol 7: 625-655.
4. Jäättelä M. (1991) Biologic activities and mechanisms of action of tumor necrosis factor-α/cachectin. Lab Invest 64: 724-742.
5. Vassalli P. (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411-452.
6. Tracey KJ, Cerami A. (1993) Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 9: 317-433.
7. Paul WE, Seder RA. (1994) Lymphocyte responses and cytokines. Cell 76: 241-251.
8. Heller RA, Krönke M. (1994) Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol 126: 5-9.
9. Cleveland JL, Ihle JN. (1995) Contenders in FasL/TNF death signaling. Cell 81: 479-482.
10. Smith CA, Farrah T, Goodwin RG. (1994) The TNF receptor superfamily of cellular, and viral proteins: Activation, costimulation, and death. Cell 76: 959-962.
11. Selmaj K et al. (1991) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invests?: 949-954.
12. Cannella B, Raine CS. (1991) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37: 424-435.
13. Brosnan CS, Selmaj K, Raine CS. (1988) Hypothesis: A role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol 18: 87-94.
14. Selmaj KW, Raine CS. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-346.
15. Selmaj K et al. (1991) Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 147: 522-529.
16. Powell MB et al. (1990) Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 2: 540-544.
17. Ruddle NH et al. (1990) An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 172: 193-200.
18. Selmaj K, Raine, CS, Cross AH. (1991) Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 30: 694-700.
19. Beck J et al. (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Act Neurol Scand 78: 318-323.
20. Sharief MK, Hentges R. (1991) Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 325: 467-472.
21. Rudick RA, Ransohoff RM. (1992) Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch Neurol 49: 265-270.
22. Chofflon M et al. (1992) Tumor necrosis factor α production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 3: 523-531.
23. Imamura K et al. (1993) Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 87: 281-265.
24. Reickmann P et al. (1994) Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 44: 1523-1526.
25. Spuler S et al. (1996) Multiple sclerosis: Prospective analysis of TNF-α and 55kD TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol, in press.
26. Zipp F et al. (1995) Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor-alpha by antigen-specific T cell lines from HLA-DR2 positive individuals Ann Neurol 38: 723-730.
27. Myers LW et al. (1995) Pentoxifylline not a promising treatment for multiple sclerosis. Neurology 45 (Suppl. 4):A419.
28. Sinha B et al. (1995) Enhanced tumor necrosis factor suppression and cyclic monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 25: 147-153.